S Zoppi1, J L Madrigal, J R Caso, M S García-Gutiérrez, J Manzanares, J C Leza, B García-Bueno. 1. Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain; Instituto UCM de Investigación en Neuroquímica, Madrid, Spain.
Abstract
BACKGROUND AND PURPOSE: Stress exposure produces excitotoxicity and neuroinflammation, contributing to the cellular damage observed in stress-related neuropathologies. The endocannabinoids provide a homeostatic system, present in stress-responsive neural circuits. Here, we have assessed the possible regulatory role of cannabinoid CB2 receptors in stress-induced excitotoxicity and neuroinflammation. EXPERIMENTAL APPROACH: We used wild type (WT), transgenic overexpressing CB2 receptors (CB2xP) and CB2 receptor knockout (CB2-KO) mice exposed to immobilization and acoustic stress (2 h·day(-1) for 4 days). The CB2 receptor agonist JWH-133 was administered daily (2 mg·kg(-1), i.p.) to WT and CB2-KO animals. Glutamate uptake was measured in synaptosomes from frontal cortex; Western blots and RT-PCR were used to measure proinflammatory cytokines, enzymes and mediators in homogenates of frontal cortex. KEY RESULTS: Increased plasma corticosterone induced by stress was not modified by manipulating CB2 receptors. JWH-133 treatment or overexpression of CB2 receptors increased control levels of glutamate uptake, which were reduced by stress back to control levels. JWH-133 prevented the stress-induced increase in proinflammatory cytokines (TNF-α and CCL2), in NF-κB, and in NOS-2 and COX-2 and in the consequent cellular oxidative and nitrosative damage (lipid peroxidation). CB2xP mice exhibited anti-inflammatory or neuroprotective actions similar to those in JWH-133 pretreated animals. Conversely, lack of CB2 receptors (CB2-KO mice) exacerbated stress-induced neuroinflammatory responses and confirmed that effects of JWH-133 were mediated through CB2 receptors. CONCLUSIONS AND IMPLICATIONS: Pharmacological manipulation of CB2 receptors is a potential therapeutic strategy for the treatment of stress-related pathologies with a neuroinflammatory component, such as depression.
BACKGROUND AND PURPOSE: Stress exposure produces excitotoxicity and neuroinflammation, contributing to the cellular damage observed in stress-related neuropathologies. The endocannabinoids provide a homeostatic system, present in stress-responsive neural circuits. Here, we have assessed the possible regulatory role of cannabinoid CB2 receptors in stress-induced excitotoxicity and neuroinflammation. EXPERIMENTAL APPROACH: We used wild type (WT), transgenic overexpressing CB2 receptors (CB2xP) and CB2 receptor knockout (CB2-KO) mice exposed to immobilization and acoustic stress (2 h·day(-1) for 4 days). The CB2 receptor agonist JWH-133 was administered daily (2 mg·kg(-1), i.p.) to WT and CB2-KO animals. Glutamate uptake was measured in synaptosomes from frontal cortex; Western blots and RT-PCR were used to measure proinflammatory cytokines, enzymes and mediators in homogenates of frontal cortex. KEY RESULTS: Increased plasma corticosterone induced by stress was not modified by manipulating CB2 receptors. JWH-133 treatment or overexpression of CB2 receptors increased control levels of glutamate uptake, which were reduced by stress back to control levels. JWH-133 prevented the stress-induced increase in proinflammatory cytokines (TNF-α and CCL2), in NF-κB, and in NOS-2 and COX-2 and in the consequent cellular oxidative and nitrosative damage (lipid peroxidation). CB2xP mice exhibited anti-inflammatory or neuroprotective actions similar to those in JWH-133 pretreated animals. Conversely, lack of CB2 receptors (CB2-KO mice) exacerbated stress-induced neuroinflammatory responses and confirmed that effects of JWH-133 were mediated through CB2 receptors. CONCLUSIONS AND IMPLICATIONS: Pharmacological manipulation of CB2 receptors is a potential therapeutic strategy for the treatment of stress-related pathologies with a neuroinflammatory component, such as depression.
Authors: Alexander Ternianov; José M Pérez-Ortiz; María E Solesio; María S García-Gutiérrez; Antonio Ortega-Álvaro; Francisco Navarrete; Carlos Leiva; María F Galindo; Jorge Manzanares Journal: Neurobiol Aging Date: 2010-10-27 Impact factor: 4.673
Authors: Juan G Zarruk; David Fernández-López; Isaac García-Yébenes; María S García-Gutiérrez; José Vivancos; Florentino Nombela; Magdalena Torres; María C Burguete; Jorge Manzanares; Ignacio Lizasoain; María A Moro Journal: Stroke Date: 2011-10-20 Impact factor: 7.914
Authors: Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares Journal: Neuropsychopharmacology Date: 2011-03-23 Impact factor: 7.853
Authors: Ana María Martín-Moreno; Begoña Brera; Carlos Spuch; Eva Carro; Luis García-García; Mercedes Delgado; Miguel A Pozo; Nadia G Innamorato; Antonio Cuadrado; María L de Ceballos Journal: J Neuroinflammation Date: 2012-01-16 Impact factor: 8.322
Authors: Shane Rowley; Xiaofei Sun; Isabel V Lima; Alexandra Tavenier; Antonio Carlos Pinheiro de Oliveira; Sudhansu K Dey; Steve C Danzer Journal: Epilepsia Date: 2017-11-03 Impact factor: 5.864
Authors: Henry L Blanton; Robert C Barnes; Melissa C McHann; Joshua A Bilbrey; Jenny L Wilkerson; Josée Guindon Journal: Pharmacol Biochem Behav Date: 2021-01-12 Impact factor: 3.533
Authors: Chaela Presley; Ammaar Abidi; Satyendra Suryawanshi; Suni Mustafa; Bernd Meibohm; Bob M Moore Journal: Pharmacol Res Perspect Date: 2015-07-06